NO318910B1 - Proteaseinhibitorer, fremgangsmate for syntese og anvendelse derav samt farmasoytisk preparat - Google Patents

Proteaseinhibitorer, fremgangsmate for syntese og anvendelse derav samt farmasoytisk preparat Download PDF

Info

Publication number
NO318910B1
NO318910B1 NO20013124A NO20013124A NO318910B1 NO 318910 B1 NO318910 B1 NO 318910B1 NO 20013124 A NO20013124 A NO 20013124A NO 20013124 A NO20013124 A NO 20013124A NO 318910 B1 NO318910 B1 NO 318910B1
Authority
NO
Norway
Prior art keywords
methyl
carboxylic acid
azepan
amide
butyl
Prior art date
Application number
NO20013124A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013124L (no
NO20013124D0 (no
Inventor
Daniel Frank Veber
Dennis Shinji Yamashita
Jr Robert Wells Marquis
Maxwell David Cummings
Yu Ru
Scott Kevin Thompson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20013124L publication Critical patent/NO20013124L/no
Publication of NO20013124D0 publication Critical patent/NO20013124D0/no
Publication of NO318910B1 publication Critical patent/NO318910B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20013124A 1998-12-23 2001-06-22 Proteaseinhibitorer, fremgangsmate for syntese og anvendelse derav samt farmasoytisk preparat NO318910B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11363698P 1998-12-23 1998-12-23
US16458199P 1999-11-10 1999-11-10
PCT/US1999/030730 WO2000038687A1 (en) 1998-12-23 1999-12-21 Protease inhibitors

Publications (3)

Publication Number Publication Date
NO20013124L NO20013124L (no) 2001-06-22
NO20013124D0 NO20013124D0 (no) 2001-06-22
NO318910B1 true NO318910B1 (no) 2005-05-23

Family

ID=26811293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013124A NO318910B1 (no) 1998-12-23 2001-06-22 Proteaseinhibitorer, fremgangsmate for syntese og anvendelse derav samt farmasoytisk preparat

Country Status (24)

Country Link
US (2) US20020147188A1 (enExample)
EP (1) EP1158986A4 (enExample)
JP (1) JP2002533397A (enExample)
KR (1) KR100630986B1 (enExample)
CN (1) CN1253441C (enExample)
AT (1) ATE411294T1 (enExample)
AU (1) AU768565B2 (enExample)
BR (1) BR9916488A (enExample)
CA (1) CA2356671A1 (enExample)
CZ (1) CZ20012277A3 (enExample)
DE (1) DE69939752D1 (enExample)
DZ (1) DZ2977A1 (enExample)
ES (1) ES2315456T3 (enExample)
GC (1) GC0000178A (enExample)
HK (1) HK1043536A1 (enExample)
HU (1) HUP0104768A3 (enExample)
IL (2) IL143142A0 (enExample)
NO (1) NO318910B1 (enExample)
NZ (1) NZ511710A (enExample)
PE (1) PE20001340A1 (enExample)
PL (1) PL350132A1 (enExample)
TR (1) TR200101869T2 (enExample)
UY (1) UY25874A1 (enExample)
WO (1) WO2000038687A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1229911A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1351930A4 (en) * 1999-11-10 2004-09-15 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1229914A4 (en) * 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034155A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034159A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513928A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1231923A4 (en) * 1999-11-10 2003-05-14 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034600A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1235577A4 (en) * 1999-11-10 2003-04-09 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034599A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1229912A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
EA005893B1 (ru) * 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
CO5280088A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
CO5280093A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Metodos de tratamiento
CN1444481A (zh) * 2000-06-14 2003-09-24 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
AU2001286983A1 (en) * 2000-09-01 2002-03-13 Smith Kline Beecham Corporation Method of treatment
CN1635903A (zh) * 2000-11-22 2005-07-06 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
PL204456B1 (pl) 2001-02-20 2010-01-29 Chugai Pharmaceutical Co Ltd Związki azolowe, ich zastosowanie i środek farmaceutyczny
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
JP2004527575A (ja) * 2001-05-17 2004-09-09 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
AU2003263738A1 (en) * 2002-05-22 2003-12-02 Smithkline Beecham Corporation Protease inhibitors
WO2003099844A2 (en) * 2002-05-22 2003-12-04 Smithkline Beecham Corporation Protease inhibitors
KR100962972B1 (ko) * 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
CA2500317A1 (en) * 2002-10-08 2004-04-22 Merck Frosst Canada & Co. 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
PL2910551T3 (pl) 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
ES2309563T3 (es) 2003-08-01 2008-12-16 Chugai Seiyaku Kabushiki Kaisha Compuestos de piperidina utiles como inhibidores de malonil coenzima a descarboxilasa.
ES2378418T3 (es) 2003-08-01 2012-04-12 Chugai Seiyaku Kabushiki Kaisha Compuestos de azol basados en cianoguanidina útiles como inhibidores de malonil-coadescarboxilasa
WO2005011670A1 (en) * 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
AU2005203920A1 (en) * 2004-01-08 2005-07-21 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
US20070293477A1 (en) * 2004-09-07 2007-12-20 Smithkline Beecham Corporation Novel Compounds
US20090264479A1 (en) * 2005-07-26 2009-10-22 Cameron Black Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
CA2647903C (en) 2006-03-30 2016-12-13 Ptc Therapeutics, Inc. Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
BR112013029672A2 (pt) 2011-05-16 2017-01-17 Bayer Ip Gmbh uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
MX2018005361A (es) 2015-10-30 2018-06-07 Ptc Therapeutics Inc Metodos para tratar epilepsia.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195287B (it) * 1981-11-05 1988-10-12 Ausonia Farma Srl Derivato tiazolico,procedimento per la sua preparazione e relative composizioni farmaceutiche
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
EP0603769B1 (en) * 1992-12-25 1998-09-16 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives
JPH06199850A (ja) * 1992-12-28 1994-07-19 Tanabe Seiyaku Co Ltd インドール含有ペプチド及びその製法
US5883121A (en) * 1995-12-12 1999-03-16 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivative or salt thereof, and medicine comprising the same
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
WO2001034599A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513928A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1235577A4 (en) * 1999-11-10 2003-04-09 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1229912A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1351930A4 (en) * 1999-11-10 2004-09-15 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1229911A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034155A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1229914A4 (en) * 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034600A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
NL1013996C2 (nl) * 1999-12-30 2001-07-03 Innas Free Piston Bv Vrijezuiger aggregaat voor opwekken van hydraulische energie.

Also Published As

Publication number Publication date
HUP0104768A2 (hu) 2002-04-29
HK1043536A1 (zh) 2002-09-20
NZ511710A (en) 2003-12-19
TR200101869T2 (tr) 2002-01-21
ES2315456T3 (es) 2009-04-01
UY25874A1 (es) 2001-08-27
WO2000038687A1 (en) 2000-07-06
CN1350458A (zh) 2002-05-22
NO20013124L (no) 2001-06-22
IL143142A0 (en) 2002-04-21
PE20001340A1 (es) 2001-01-28
KR20010089677A (ko) 2001-10-08
AU1941100A (en) 2000-07-31
CZ20012277A3 (cs) 2001-11-14
HUP0104768A3 (en) 2002-05-28
IL143142A (en) 2006-08-20
DZ2977A1 (fr) 2004-03-15
EP1158986A4 (en) 2002-03-27
EP1158986A1 (en) 2001-12-05
AU768565B2 (en) 2003-12-18
ATE411294T1 (de) 2008-10-15
CA2356671A1 (en) 2000-07-06
JP2002533397A (ja) 2002-10-08
BR9916488A (pt) 2001-10-09
US20020147188A1 (en) 2002-10-10
KR100630986B1 (ko) 2006-10-09
US20030225061A1 (en) 2003-12-04
PL350132A1 (en) 2002-11-04
CN1253441C (zh) 2006-04-26
NO20013124D0 (no) 2001-06-22
DE69939752D1 (de) 2008-11-27
GC0000178A (en) 2006-03-29

Similar Documents

Publication Publication Date Title
NO318910B1 (no) Proteaseinhibitorer, fremgangsmate for syntese og anvendelse derav samt farmasoytisk preparat
AU2001243441B2 (en) Protease inhibitors
AU2001243441A1 (en) Protease inhibitors
BG107327A (bg) Инхибитори на протеаза
US7405209B2 (en) Protease inhibitors
EP1401453A2 (en) Protease inhibitors
EP1384713A1 (en) 4-amino-azepan-3-one derivatives as protease inhibitors
AU2003261482B2 (en) Protease inhibitors
KR20040004445A (ko) 프로테아제 억제제
MXPA01006613A (en) Protease inhibitors
HK1063051A (en) 4-amino-azepan-3-one derivatives as protease inhibitors